Vestal Point Capital LP Has $30.97 Million Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Vestal Point Capital LP has increased its stake in Structure Therapeutics by 3.7%, holding approximately 1.79 million shares valued at about $30.97 million, making it the firm's 15th largest position.
• Structure Therapeutics reported a loss of ($0.36) earnings per share, missing estimates, with analysts predicting the company will post a total of -$0.82 EPS for the current fiscal year.
• Despite recent markdowns in target prices by various brokerages, Structure Therapeutics maintains an average stock rating of "Buy" with a price target of approximately $75.71.

Vestal Point Capital LP increased its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 3.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,788,990 shares of the company's stock after purchasing an additional 63,990 shares during the quarter. Structure Therapeutics makes up approximately 2.2% of Vestal Point Capital LP's holdings, making the stock its 15th biggest holding. Vestal Point Capital LP owned approximately 3.12% of Structure Therapeutics worth $30,967,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in GPCR. GF Fund Management CO. LTD. acquired a new stake in Structure Therapeutics in the 4th quarter valued at about $34,000. National Bank of Canada FI increased its position in Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after acquiring an additional 2,766 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Structure Therapeutics by 673.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after acquiring an additional 3,549 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after acquiring an additional 3,213 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its position in shares of Structure Therapeutics by 12.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after buying an additional 843 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Price Performance

GPCR traded up $2.32 during trading on Friday, reaching $22.08. The company had a trading volume of 2,087,248 shares, compared to its average volume of 1,048,602. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $13.22 and a 12 month high of $45.37. The business's fifty day moving average price is $18.86 and its 200 day moving average price is $20.73. The company has a market cap of $1.27 billion, a P/E ratio of -21.03 and a beta of -1.88.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). As a group, sell-side analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. JMP Securities lowered their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. Guggenheim lowered their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, June 23rd. Finally, HC Wainwright reduced their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.